Designing protein materials for stable, accessible biologics.

Still Velocity is building computationally designed protein materials to make fragile biologics more stable, accessible, and deployable.

Modern biotechnology can create extraordinary medicines, vaccines, enzymes, and cell-based tools. But many of these systems remain physically fragile. They depend on cold-chain logistics, narrow handling conditions, and formulation strategies that were not built for the pace or breadth of the next generation of biological products.

Our mission is to change that.

The modern pharmaceutical cold chain costs tens of billions of dollars to operate each year and contributes to significant product waste when temperature excursions occur. Our novel proteins have promising potential to reduce cold-chain dependence and protect biological cargo at ambient temperature, creating an opportunity to improve global health and expand access to critical vaccines and biologics, including in remote regions and harsh climates.

The goal is simple: make advanced biologics easier to manufacture, transport, store, and use without compromising safety, quality, or public health.

The cold chain is one of biotechnology’s quiet constraints.

Temperature sensitivity increases cost, limits distribution, complicates field use, and narrows access. These constraints matter in medicine, agriculture, industrial biotechnology, and emergency response. They are especially consequential when biological products need to reach places where infrastructure is limited or where speed matters.

Still Velocity is focused on the underlying physical problem: how to design protective molecular environments around biological systems before they fail.

We combine protein design, biophysical modeling, biosafety screening, and experimental validation to discover synthetic proteins with useful protective behavior.

Rather than relying only on natural proteins or broad empirical screening, we use computational methods to search design space deliberately. Our platform evaluates candidates across multiple dimensions, including sequence architecture, disorder, charge patterning, structural features, predicted solubility, formulation-relevant behavior, and safety-relevant biological risk.

The result is a disciplined discovery process: generate, screen, validate, learn, and improve.

Still Velocity is building for translation into real-world biological systems, where safety is not a secondary consideration. It is a design requirement.

We are committed to developing protein excipients through a responsible framework that incorporates biosafety screening, immunogenicity awareness, experimental validation, and careful evaluation before any material is advanced toward use with therapeutic cargo. Our work is guided by the principle that broader access to biologics must be achieved without lowering standards for product quality, patient safety, or regulatory readiness.

Public health is the reason this work matters. A more stable biologic supply chain can reduce waste, improve emergency preparedness, support more reliable vaccine and therapeutic distribution, and help extend the reach of modern biotechnology to communities that are underserved by today’s infrastructure.

We believe useful biotechnology should be technically rigorous, experimentally honest, safety-conscious, and built for translation.

That means we do not treat computation as a substitute for validation. We use it to make better experimental decisions. We do not optimize for novelty alone. We optimize for molecules that can survive contact with real constraints: manufacturability, biosafety, formulation compatibility, regulatory expectations, and measurable performance.

Still Velocity exists to move biological systems from fragility toward resilience.

A future with more stable biologics is a future with lower distribution costs, broader worldwide access, faster deployment, and more flexible product design.

We are building toward a world where biological products are not limited by the infrastructure around them, and where stabilization can be designed into a product from the beginning.